sur INNATE PHARMA (EPA:IPH)
Innate Pharma to Participate in Key Investor Conferences
Innate Pharma SA, based in Marseille, France, will be engaging with investors through participation in two significant virtual healthcare conferences in June 2025. The company will be represented at the H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference on June 24, 2025, and the Wolfe Research Virtual Biotech Day on June 26, 2025. These events provide a platform for Innate Pharma to showcase its advancements in cancer immunotherapies, specifically its focus on multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies.
Innate Pharma is recognized for its ANKET® platform and collaborates with notable partners like Sanofi and AstraZeneca. The company is publicly traded on Euronext Paris and Nasdaq. Innate continues to expand its innovative portfolio, aiming to address various tumor types and enhance cancer treatment outcomes globally.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INNATE PHARMA